Davenport v. Blue Cross of California

52 Cal. App. 4th 435, 60 Cal. Rptr. 2d 641, 97 Cal. Daily Op. Serv. 752, 97 Daily Journal DAR 1069, 1997 Cal. App. LEXIS 64
CourtCalifornia Court of Appeal
DecidedJanuary 30, 1997
DocketC022965
StatusPublished
Cited by40 cases

This text of 52 Cal. App. 4th 435 (Davenport v. Blue Cross of California) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Davenport v. Blue Cross of California, 52 Cal. App. 4th 435, 60 Cal. Rptr. 2d 641, 97 Cal. Daily Op. Serv. 752, 97 Daily Journal DAR 1069, 1997 Cal. App. LEXIS 64 (Cal. Ct. App. 1997).

Opinion

Opinion

SIMS, Acting P. J.

In this action alleging tortious breach of a health insurance contract, defendant Blue Cross of California (Blue Cross) appeals from an order granting a preliminary injunction in favor of plaintiff Dorothy H. Davenport, enjoining Blue Cross from refusing coverage for medical treatment for ovarian cancer pending arbitration. Blue Cross contends, among other things, that the Federal Arbitration Act (FAA) (9 U.S.C. § 1 et seq.) precludes the granting of the preliminary injunction because plaintiff failed to justify the injunction as necessary to preserve the effectiveness of arbitration. We shall conclude that, under both the FAA and California law, the trial court may grant provisional relief pending contractual arbitration only where it is necessary to preserve the effectiveness of arbitration—a test which plaintiff failed to meet in this case. We shall therefore reverse.

*440 Factual and Procedural Background

Plaintiff, a special education teacher in Calaveras County, is covered for major medical and health expenses through a plan provided by the Tuolumne Joint Powers Authority (JPA). The JPA plan is entirely self-funded. Blue Cross is compensated for administering and servicing the JPA plan. The JPA is solely responsible for funding the payment of claims under the JPA .plan. Blue Cross has no financial obligation under the plan and passes through 100 percent of the cost of any claims to the JPA.

In September 1994, plaintiff was diagnosed with ovarian cancer. Surgery was performed, and plaintiff was placed on a regimen of six rounds of standard chemotherapy. A “second look” surgery in May 1995 revealed that, although the initial regimen of chemotherapy was 99 percent effective, there was evidence of some remaining cancer. A second regimen of six rounds of chemotherapy was then administered. Plaintiff’s cancer responded positively to this second regimen of chemotherapy, which was completed in November 1995. Her primary oncologist thereafter found no demonstrable evidence of disease.

Plaintiff consulted with doctors who recommended treatment combining high-dose chemotherapy with autologous bone marrow transplant (HDCT with ABMT), to be provided at the Stanford University Medical Center, the goal of which was to prevent recurrence of the cancer. In HDCT with ABMT, bone marrow or peripheral stem cells are drawn from the patient and stored. HDCT is then administered, in a procedure designed to destroy the cancer cells. An unavoidable side effect of HDCT is destruction of the patient’s bone marrow and suppression of the autoimmune system and clotting abilities. In an attempt to combat the side effects, the previously drawn bone marrow or peripheral cells are reinfused into the patient, with the goal of repopulating the patient’s bone marrow. Up to 5 percent of the patients who have HDCT with ABMT die from the treatment itself, a percentage which one doctor characterized as low.

Plaintiff submitted a request to Blue Cross to obtain precertification under the JPA plan for HDCT with ABMT. Blue Cross referred the request for review to Dr. George Au, an oncologist and medical consultant to Blue Cross. After review, Dr. Au concluded HDCT with ABMT, as a treatment for plaintiff’s epithelial cell ovarian cancer, would be “investigational” within the meaning of the contract. The JPA plan excludes coverage for “investigative procedures,” which are defined under the policy as “those [procedures] that have progressed to limited use on humans, but which are not widely accepted as proven and effective procedures within the organized *441 medical community.” Dr. Au’s conclusion was consistent with a May 1995 determination by Blue Cross’s medical advisory panel of 16 physicians, that HDCT with ABMT was generally accepted in the medical community as safe and effective for certain medical conditions, but not for the type of cancer (epithelial cell ovarian cancer) which afflicted plaintiff.

On December 5, 1995, Blue Cross informed plaintiff in writing that her request for precertification for HDCT with ABMT treatment for her ovarian cancer was denied. Blue Cross further informed plaintiff: “If you do not accept the decision, you must submit your dispute to binding arbitration according to your contract. You must ask for arbitration in writing.”

The JPA plan’s arbitration clause provides:

“Binding Arbitration

“Any dispute between the Member and Blue Cross regarding the decision of Blue Cross must be submitted to binding arbitration if the amount in dispute exceeds the jurisdictional limits of the small claims court. This arbitration is begun by the Member making written demand on Blue Cross.

“This arbitration will be held before a designated neutral arbitrator appointed by the county medical association of the county in which the services were provided. If the county medical association declines or is unable to appoint an arbitrator, the arbitration will be conducted according to the rules of the American Arbitration Association.

“Any dispute regarding a claim for damages within the jurisdictional limits of the small claims court will be resolved in such court.

“The Arbitration Findings Will Be Final and Binding.”

Plaintiff did not take any action to pursue arbitration.

Instead, on December 28, 1995, plaintiff filed a complaint in Amador County Superior Court. The complaint was captioned: “Tortious Breach of Insurance Contract (Compensatory and Punitive Damages) [U 1. Declaratory Relief [f] 2. Injunctive Relief [^Q 3. Breach of Duty of Good Faith and Fair Dealing [f] 4. Breach of Contract [H 5. Negligence.” The matter was assigned to the court’s fast-track calendar.

On January 17, 1996, plaintiff served the complaint on Blue Cross and applied to the trial court for a preliminary injunction pursuant to Code of *442 Civil Procedure section 525 et seq. Plaintiff sought an injunction enjoining Blue Cross from denying coverage for the treatment, which carried an estimated cost of $150,000. Plaintiff submitted declarations from doctors urging the treatment. 1 Dr. Wendy Hu of Stanford stated in a declaration that plaintiff had a stage of cancer (stage IIIC) with a “relatively bleak prognosis,” and she was “at extremely high-risk for recurrence.” Dr. Hu attested that without HDCT with ABMT, plaintiff’s life expectancy over five years would be less than 20 percent. Dr. Hu said: “HDCT with ABMT offers Dorothy Davenport a greater possibility that her disease will respond to treatment and offers a small but hopeful chance that her cancer will be cured.” Dr. Hu’s declaration said: “The statistical odds are that within an extremely short time (several months), Dorothy Davenport will relapse. . . . HD . . . Current evidence demonstrates that administration of HDCT with ABMT now can lead to a longer period of disease free survival. However, the window of opportunity that now exists for HDCT with ABMT can close if the tumor is given sufficient time to regrow.” 2 Plaintiff filed a declaration attesting: “I am unable to fund the costs of HDCT with ABMT.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

CJ 4DPlex America v. Choi CA2/1
California Court of Appeal, 2025
Save Petaluma v. City of Petaluma CA1/2
California Court of Appeal, 2025
Preovolos v. Preovolos CA4/1
California Court of Appeal, 2024
Capra v. Ledesma CA2/4
California Court of Appeal, 2024
eGumball v. Merrick Bank Corp. CA4/3
California Court of Appeal, 2023
Ramos v. Monschein Industries, Inc. CA5
California Court of Appeal, 2022
People v. Escobedo-Yagut CA1/1
California Court of Appeal, 2022
Smith v. Sprouts Farmers Market CA2/3
California Court of Appeal, 2022
Olson v. Hornbrook Community Services District
California Court of Appeal, 2021
Paula v. Lutteroth CA4/1
California Court of Appeal, 2021
McKissock v. Kashfian CA2/3
California Court of Appeal, 2021
Fregoso v. Eat Club CA6
California Court of Appeal, 2020
Fierro v. Landry's Restaurant Inc.
California Court of Appeal, 2018
Fierro v. Landry's Rest. Inc.
232 Cal. Rptr. 3d 651 (California Court of Appeals, 5th District, 2018)
URS Corp. v. Atkinson/Walsh Joint Venture
California Court of Appeal, 2017

Cite This Page — Counsel Stack

Bluebook (online)
52 Cal. App. 4th 435, 60 Cal. Rptr. 2d 641, 97 Cal. Daily Op. Serv. 752, 97 Daily Journal DAR 1069, 1997 Cal. App. LEXIS 64, Counsel Stack Legal Research, https://law.counselstack.com/opinion/davenport-v-blue-cross-of-california-calctapp-1997.